Señales en vivo de ALM.MC | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:35):

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally...

Stats
Volumen de hoy	266 157
Volumen promedio	184 103
Capitalización de mercado	1.79B
EPS	€0 ( 2024-02-18 )
Próxima fecha de ganancias	( €0 ) 2024-05-12
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-42.85
ATR14	€0.00700 (0.08%)

Volumen Correlación

Largo: 0.10 (neutral)

Corto: 0.50 (weak)

Signal:(42.696) Neutral

Almirall, S.A. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Almirall, S.A. Correlación - Moneda/Commodity

-0.02
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.69
( moderate negative )

0.00
( neutral )

0.41
( neutral )

Almirall, S.A. Finanzas

Annual	2023
Ingresos:	€898.80M
Beneficio Bruto:	€581.40M (64.69 %)
EPS:	€-0.200

FY	2023
Ingresos:	€898.80M
Beneficio Bruto:	€581.40M (64.69 %)
EPS:	€-0.200

FY	2022
Ingresos:	€863.25M
Beneficio Bruto:	€680.78M (78.86 %)
EPS:	€0.0237

FY	2021
Ingresos:	€827.20M
Beneficio Bruto:	€655.61M (79.26 %)
EPS:	€-0.233

Financial Reports:

No articles found.

Almirall, S.A.

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.